文献速递骨软组织肉瘤与黑色素瘤

普萘洛尔超适应症治疗黑色素瘤:队列研究结果

Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study.
PubMed 文献 · JAMA Oncol · 2018-02-08

IMPORTANCE: Preclinical and retrospective studies showed that β-blockers inhibit angiogenesis and disrupt migration of melanoma cells via inhibition of noradrenaline-dependent responses.…

要点

  • 诊断时使用普萘洛尔与黑色素瘤复发风险降低约80%相关。
  • 研究为超适应症用药的前瞻性队列,非随机对照试验。
  • 结果与此前β受体阻滞剂保护厚型皮肤黑色素瘤患者的观察一致。

核心结论

  • 在缺乏随机双盲安慰剂对照试验的情况下,本研究是首个普萘洛尔超适应症治疗黑色素瘤的研究,结果证实β受体阻滞剂可保护厚型皮肤黑色素瘤患者免于疾病复发。

研究设计与样本

  • 前瞻性研究,纳入组织学确诊的IB至IIIA期皮肤黑色素瘤且无转移证据的患者,共53例(中位年龄63岁,四分位距48-75岁;男性33例)。
  • 两队列在基线人口学特征和主要预后因素方面可比。

主要发现

  • 主要结局为无进展生存期,疾病进展通过评估淋巴、中途或内脏转移判定,并记录死亡原因。

临床怎么用

  • 本研究结果支持β受体阻滞剂对厚型皮肤黑色素瘤患者的保护作用,与近期观察一致。
  • 研究符合肿瘤学「药物再利用」策略,即利用非肿瘤适应症的已批准药物可能为癌症患者提供更有效且廉价的治疗选择。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preclinical and retrospective studies showed that β-blockers inhibit angiogenesis and disrupt migration of melanoma cells via inhibition of noradrenaline-dependent responses. OBJECTIVE: To study the clinical effectiveness of β-blocker therapy in patients with melanoma and to determine whether propranolol improves progression-free survival in patients with melanoma. DESIGN, SETTING, AND PARTICIPANTS: We conducted a prospective study in patients treated for melanoma in our center with propranolol for off-label use. Patients with histologically confirmed stage IB to IIIA cutaneous melanoma and no evidence of metastasis were eligible for the study. At the time of diagnosis, they were asked to take propranolol (80 mg daily) as an off-label adjuvant treatment. If they accepted the treatment, they were considered part of the propranolol cohort (PROP). If they refused treatment but agreed to participate in the study control group, they were considered part of the nonpropranolol cohort (No-PROP). MAIN OUTCOMES AND MEASURES: The primary outcome was progression-free survival. Disease progression was assessed by evaluating the presence of lymphatic, in-transit, or visceral metastases, and the cause of death was recorded. RESULTS: Among the 53 patients (median [interquartile range] age 63 [48-75] years; 33 men) included in the study, 19 were eligible for the PROP cohort. Thirty-four patients otherwise eligible but unwilling to take propranolol were enrolled in the No-PROP cohort. The 2 cohorts were comparable in terms of demographic characteristics and primary prognostic factors at baseline. After adjusting for known prognostic factors, Cox models confirmed that use of propranolol at the time of diagnosis was significantly inversely associated with recurrence of melanoma with approximately an 80% risk reduction for propranolol users (hazard ratio, 0.18; 95% CI, 0.04-0.89; P = .03). CONCLUSIONS AND RELEVANCE: In the absence of randomized, double-blind, placebo-controlled clinical trials, this study is the first off-label study of which we are aware of propranolol for melanoma treatment. These results confirm recent observation that β-blockers protect patients with thick cutaneous melanoma from disease recurrence. This study is in accordance with the present policy of "drug repurposing" in oncology. Repurposing the vast arsenal of approved drugs with a nononcology primary purpose may prove an attractive and inexpensive strategy for offering more effective treatment options to patients with cancer.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. De Giorgi V, Grazzini M, Benemei S, et al. Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. JAMA Oncol. 2018. PMID: 28973254. doi:10.1001/jamaoncol.2017.2908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。